Milhan Telatar, Ph.D., is board certified in clinical molecular genetics by the American Board of Medical Genetics and Genomics. She has been serving as the director of the Clinical Molecular Diagnostic Laboratory at City of Hope, providing scientific, technical, regulatory and operational oversight to the lab. She has demonstrated records of successful design, development and deployment of multiple molecular assays, including HopeSeq panels to meet the growing need at City of Hope and in the community for more comprehensive molecular testing in solid tumors, hematological and hereditary cancers. These panels have strengthened City of Hope’s leading position in cancer research and treatment and have further expanded its position as a leading provider of precision medicine.
After completing her postgraduate studies at Bogazici University in Istanbul, Turkey, Dr. Telatar received a Ph.D. in human genetics and was honored with the Ph.D. Thesis Award of the Bogazici University Research Fund. She then completed a fellowship in molecular genetics in the Department of Pathology and Laboratory Medicine at University of California Los Angeles (UCLA). She then furthered her training with a fellowship in the UCLA Intercampus Medical Genetics Program and conducted research as part of a Research and Development Fellowship at the Lymphoma Research Foundation of America Inc.
Dr. Telatar is a fellow of the American College of Medical Genetics and Genomics and an active member of the American Society of Human Genetics and the Association for Molecular Pathology. She has published peer-reviewed articles, abstracts and book chapters and has received research grants from the National Institutes of Health and the Centers for Disease Control and Prevention.